The study investigated the clinical efficacy of topical bimiralisib 2.0% gel, an inhibitor of phosphoinositide-3-kinases (PI3K), and the mammalian target of rapamycin (mTOR) in healthy patients and such with Mycosis fungoides compared to Placebo. This cancer belongs to the primary cutaneous T-cell lymphomas (CTCLs) and presents with ​​plaques and nodules composed of lymphocytes.

The clinical researchers used Scarletred®Vision and its App for photo documentation during the treatment and duration of the clinical study. Patients documented their treatment progression daily, while the study team used the software to quantify the erythema of a single target lesion. Due to no clinical activity, more research needs to be explored as topical therapeutic drug, however, meaningful cutaneous drug levels were detected.

Read the full publication here.